Interim report
Page 1
A dose of life THRU ONLINE FILING November 5, 2026 BSE Ltd. Phiroze Jeejeebhoy Towers Dalai Street Mumbai 400 023 Scrip Code - 524494 National Stock Exchange India Limited, Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra - (East). Mumbai-400051. Scrip Code : IPCALAB Dear Sirs, Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith our Standalone and Consolidated Unaudited Financial Results along with limited review reports of the Company’s Statutory Auditors thereon for the second Quarter and half year ended 30th September, 2026, which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai. We are also enclosing herewith press release issued by the Company in respect of its Q2 / H1 FY27 unaudited financial Results. Kindly note that the Board meeting started at 11.30 a.m. and concluded at 1.35 p.m. Thanking you Yours faithfully For Ipca Laboratories Limited Harish P. Kamath Corporate Counsel & Company Secretary ACS 6792 Enel: a/a Ipca Laboratories Ltd. 125, <andivli Industrial rstate, Kandiva (West), M jmbai 400 067 (Maharashtra), India 'teqd Office 48, Kandivli Industrial Estate. Kandivli (West). Mumbai 400 067 (Maharashtra), ndia | I -91 22 6647 4444 I: ipca@ipca.corn CIV L24239MII1949PLC007837 -91 22 62'0 5000 I • 91 22 6710 5006
Page 2
Ipca Laboratories Limited Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067 CIN : L24239MH1949PLC007837 Tel:+91 22 6647 4444, E-mail: investors@ipca.com Website : www.ipca.com STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 (? Crores) Half Year Ended Year EndedQuarter EndedParticularsSr. Sept 30, 2025 Unaudited March 31, 2026 Audited Sept 30, 2025 Unaudited Sept 30, 2026 Unaudited Sept 30, 2026 Unaudited June 30, 2026 Unaudited No. 4,374.85 3,677.22 7,336.752,255.61 2,119.24 1,930.32Revenue from operationsI 36.34 46.94 94.6418.92 17.42 21.92II Other Income 3,724.16 7,431.392,274.53 2,136.66 1,952.24 4,411.19Total Income (l+ll) IV Expenses a) Cost of materials consumed b) Purchases of stock-in-trade c) Changes in inventories of finished goods, work-in-progress and stock-in-trade d) Employee benefits expense 377.32 939.92 772.91 1,568.33494.16 445.76 112.99 110.75 89.40 223.74 173.51 348.51 (26.11) (16.10) 43.93 (42.21) 12.12 (60.05) 945.81 821.30 1,655.90478.49 467.32 411.39 972e) Finance costs 4.68 5.04 11.46 23.52 43.51 152.20f) Depreciation and amortisation expense 77.59 74.61 66.86 129.99 268.87 g) Other expenses 599.02 533.87 543.57 1,132.89 1,025.75 2,043.78 Total Expenses (IV) 1,740.82 1,621.25 1,543.93 3,362.07 2,959.10 5,868.84 V Profit before exceptional items and tax (lll-IV) Exceptional items : (Income) / expenses (Refer note No.4) Profit before tax (V-VI) Tax Expense 533.71 515.41 408.31 1,049.12 765.06 1,562.55 VI 30.42 VII 533.71 515.41 408.31 1,049.12 765.06 1,532.13 VIII -Current tax 141.42 130.43 104.52 271.85 197.18 405.25 -Short / (Excess) provision of earlier years -Deferred tax liability / (asset) (0.31) (0.31) (3.13) (2.51)5.00 12.00 (0.95) 17.00 1.10 IX Profit for the period from continuing operations (VII-VIII) 387.29 373.29 304.74 760.58 566.78 1,132.52 Other Comprehensive Income A) Items that will not be reclassified to profit or loss X - Actuarial gain/(loss) 1.52 (18.14) 2 17 (16.62) (0.13) 4.60 Tax effects thereon (0.21) (0.56) 4.254.46 0.03 (1.25) - Fair value change through Other Comprehensive Income 1.24 Tax effects thereon B) Items that will be reclassified to profit or loss - Exchange difference in translating the financial statement of foreign operation 1.861.43 0.11 0.44 1.54 0.19 Tax effects thereon (0.37) (0.03) (0.12) (0.40) (0.05) (0.50) Other Comprehensive Income / (Loss) for the period net of tax (X) 2.37 (13.60) 1.93 (11.23) 0.04 5.95 XI Total Comprehensive Income for the period (IX+X) 389.66 359.69 306.67 749.35 566.82 1,138.47 XII Paid-up equity share capital (Face value of ? 1/- each) XIII Other Equity 25.37 25.37 25.37 25.37 25.37 25.37 7,953.98 XIV Net Worth 7,979.35 XV Earnings per share (of ? 1/- each) (Not annualised): Basic / Diluted (Before Exceptional items) ( ? ) 15.27 14.71 12.01 29.98 22.34 45.84 Basic / Diluted (After Exceptional items) ( ? ) 15.27 14.71 12.01 2998 22.34 44.64 Q/'V SAU o oUJ >Q. •z V whored X \ *
Page 3
: 2: Ipca Laboratories Limited Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067 CIN : L24239MH1949PLC007837 Tel:+91 22 6647 4444, E-mail: investors@ipca.com Website : www.ipca.com UNAUDITED STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026 (? Crores) ParticularsSr. As at September 30, 2026 Unaudited As at March 31,2026 AuditedNo. A ASSETS : Non-current assets : Property, Plant and Equipment Capital work-in-progress Goodwill Other Intangible assets Intangible assets under development Right of use assets Biological assets other than bearer plant Financial Assets (i) Investments in Subsidiary/Joint Venture/Associate (ii) Other investments (iii) Loans (iv) Others Other non-current assets Total Non-current assets Current assets : Inventories Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank Balance other than (iii) above (v) Loans (vi) Others Current tax assets (net) Other current assets Total Current assets 1 (a) 2,988.89 454.84 2,871.69 447.87(b) (c) (d) 31.28 13.40 91.43 34.31 11.50 63.13 (e) (f) (9) 0.22 0.22 (h) 2,228.94 26.51 2,161.88 26.51 5.19 14.36 81.20 67.83 85.23 97.67(i) 6,023.60 5,780.50 2 (a) 1,809.37 1,707.51 (b) 645.81 1,543.92 84.60 348.03 1,272.05 311.51 51.67 39.93 12.61 2.03 38.76 14.79 (c) (d) 260.14 251.69 4,399.42 3,995.00 Total Assets 10,423.02 9,775.50 EQUITY AND LIABILITIES : Equity : Equity Share Capital Other Equity Total Equity Liabilities : Non-current liabilities : Financial Liabilities (i) Borrowings (ii) Lease liability (iii) Other financial liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Total Non-current liabilities Current liabilities : Financial Liabilities (i) Borrowings (ii) Lease liability (iii) Trade payables - Dues of micro and small enterprises - Dues of others (iv) Other financial liabilities Provisions Other current liabilities B 1 (a) 25.37 8,551.11 25.37 7,953.98(b) 8,576.48 7,979.35 2 (a) 35.00 76.42 70.00 50.13 (b) 82,04 205.69 68.58 188.69(C) (d) 399.15 377.40 ii (a) 116.68 14.07 165.16 9.93 128.72 563.43 339.89 151.59 59.13 73.88 133.46 472.09 378.11 153.13 50.30 56.57 (b) (c) (d) Current Tax Liabilities (net) fojiaB^ifofept liabilities______________ Total Equity and Liabilities C 1,447.39 1,418.75 9,775.50O 10,423.02 'Q/\, Lufel / OQ- Z:£z. X' wed
Page 4
: 3 : IPCA LABORATORIES LIMITED Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067 CIN : L24239MH1949PLC007837 Tel:+91 22 6647 4444, E-mail: investors@ipca.com Website : www.ipca.com STATEMENT OF UNAUDITED STANDALONE CASH FLOW FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026 (7 Crores) For the Half year ended Particulars September 30, 2026 Unaudited September 30, 2025 Unaudited A. Cash Flow from Operating Activities 1) Net profit before taxation and after exceptional items Adjustments for: Depreciation, amortisation and impairment expense (Profit) / Loss on sale of property, plant & equipment Exchange gain on redmption of Preference shares Net (gain) / loss on financial asset through FVTPL Property, plant & equipment scrapped/transferred Sundry balances written off/(back) Provision for doubtful debts / advances Impairment of financial assets Impairment of intangible assets Bad debts written off Foreign exchange (gain) / loss - Unrealised Fair value changes-Biological assets (gain)/loss Claim receivable written off Interest income Dividend income Interest expense 2) Operating profit before working capital changes Decrease / (Increase) in inventories Decrease / (Increase) in trade receivables Decrease / (Increase) in other financial assets Decrease / (Increase) in other assets Increase / (Decrease) in trade payables Increase / (Decrease) in other financial liabilities Increase / (Decrease) in other liabilities Increase / (Decrease) in provisions 3) Cash generated from operation Income tax paid (net) Net cash from operating activities B. Cash Flow from Investing Activities Purchase of property, plant & equipment including capital work in progress and intangible assets Capital Incentive Proceeds from sale of property,plant and equipment Proceeds from disposal of non-current assets held for sale Investment in subsidiaries Redemption of Investment in Subsidiaries Loan given - Associate & Joint Venture Loan recovered - Associate & Joint Venture Movement in other bank balances Dividend received Interest received Net cash from / (used in) investing activities C. Cash Flow from Financing Activities Increase / (decrease) in short term borrowings Repayment of long-term borrowings Payment of principal portion of Lease liability Payment of interest portion of Lease liability Interest paid Dividend paid Net cash from / (used in) financing activities Net increase / (decrease) in cash and cash equivalents ( A + B + C ) Cash and cash equivalents at beginning of year Cash and cash equivalents at end of the period Components of cash & cash equivalents : Cash and cheques on hand Balance with banks Mutual Funds Add/(Less): Fair value (gain) / loss on Mutual funds 1,049.12 765.06 152.20 (0.15) (2.61) (3.66) 129.99 0.40 (0.55) 0.11 0.96 (0.12) (0.17) 0.90 0.18 9.58 14.78 6.01 7.77 0.82 0.01 14.25 38.60 0.05 1.20 (15.72) (2.38) (8.37) (2.38) 23.529.72 168.95 205,99 1,218.07 971.05 (101.86) (272.16) (6.29) (8.15) 85.52 (37.65) 30,35 (170.59) (10.93) (25.63) 16.26 13.31 (4.78) 21.97 8.83 (4.71) (336.47) (130.04) 881.60 (250.18) 841.01 (189,46) 631.42 651.55 (337.96) (334.17) 20.96 0.96 1.29 36.90 (60.20)(67.06) 2.61 (2.35) (7.55) 3.05 5.81 50.00 82.84 2.38 2.38 15.03 9.08 (312.38) (263.62) (1.92) (81.55) (5.95) (2.91) (7.28) (152.22) (39.50) (111.84) (3.94) (1.52) (25,68) (50,74) (251.83) (233.22) 67.21 658.02 154.71 722.10 725.23 876.81 0.33 0.34 84.27 135.36 645.81 (5.18) 748.28 (7.17)640.63 741.11 725.23 876.81 By Order of the Board For Ipca Laboratories Limited^ J Jjk orato 121 & CLP, cfo / 0- Pea a o A.K. Jain \ \ Managing Director \ 1' (DIN 00012657) \ AccPPlace : Mumbai, Date : November 5, 2026 <7 <3+ * ,2*
Page 5
A: Notes: 1 The above unaudited standalone financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors at their meeting held on November 5, 2026. 2 The Statutory Auditors of the Company have carried out Limited Review of the unaudited standalone financial results and have issued an unmodified report thereon. 3 The above financial results are prepared in accordance with the Indian Accounting Standards (IND-AS) as prescribed under Section 133 of the Companies Act, 2013 and are in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 (as Amended). 4 Exceptional items: (? crores) Sr. No. Particulars Quarter Ended Half Year Ended Year Ended Sept 30, 2026 June 30, 2026 Sept 30, 2025 Sept 30, 2026 Sept 30, 2025 March 31, 2026 Impact of new Labour Codesa 30.42 Disclosure on above: a Impact of new Labour Codes On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes’) which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to gratuity and leave. The Company assessed the financial implications of these changes which has resulted in increase in gratuity and leave liability arising out of past service cost by ? 30.42 crores for the year ended March 31, 2026. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this amount as “Impact of new Labour Codes" under “Exceptional Item” in the Statement of Profit and Loss for the year ended March 31, 2026. 5 At the meeting of the Board of Directors of the Company held on June 26, 2026, it was resolved to amalgamate M/s. Krebs Biochemicals & Industries Ltd. with the Company, subject to necessary consents/approvals. The appointed date for this amalgamation is April 1, 2026. However, pending consents/approvals, no effect for this amalgamation has been given in the unaudited financial results. 6 The Company has only one operating segment viz. 'Pharmaceuticals'. 7 Figures of the previous period have been regrouped to conform to the figures of the current period's classification wherever necessary. By Order of the Board For Ipca Laboratories Limited A.K. Jain Managing Director (DIN 00012657) Place : Mumbai, Date : November 5, 2026 J 7|?yo << Uj/t) a. ^ *
Page 6
N V C 6* Associates LLP Chartered Accountants 903-904,9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email: nvc@nvc.in LIPIN ’ACM-9656 Independent Auditor's Review Report on Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2026, of Ipca Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 (as Amended) To, The Board of Directors of Ipca Laboratories Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results ("the Statement") of Ipca Laboratories Limited ("the Company") for the quarter and half year ended September 30, 2026, being submitted by the Company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time (The Listing Regulations). 2. Management's responsibility The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. This statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind-AS 34) prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion in our report on this Statement of standalone unaudited financial results based on our review. 3. Auditor's Responsibility We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
Page 7
N V C G* Associates LLP Chartered Accountants 903-904,9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email: nvc@nvc.in LLPIN - ACM-9656 4. Conclusion Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable accounting standards as specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement. For N V C & Associates LLP Chartered Accountants Firm Registration No. 106971W/W101085 QX^ = ( Mumbai IT5NJayendran J Partner M. No. 040441 Mumbai Dated: November 05, 2026 UDIN: 26040441TWBBSF4504
Page 8
Ipca Laboratories Limited Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067 GIN: L24239MH1949PLC007837 _ _ Tel:+91 22 6647 4444, E-mail: investors@ipca.com Website: www.ipca.com STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30/*2l)26 (Sj Crores) Quarter Ended Half year endedSr. No. Year endedParticulars Sept 30, 2026 Unaudited Sept 30, 2025 Unaudited Sept 30, 2026 Unaudited June 30, 2026 Unaudited Sept 30, 2025 Unaudited Mar 31, 2026 Audited Revenue from Operations Other Income I 2,909.94 25.03 2,556.50 27.86 5,698.04 50.29 2,788.10 25.26 4,865.35 60.52 9,646.33 174.4511 Total Income (1+il)111 2,584.36 5,748.33 4,925.872,934.97 2,813.36 9,820.78 IV Expenses: a) Cost of materials consumed b) Purchases of stock-in-trade c) Changes in inventories of finished goods, work-in-progress and stock-in-trade d) Employee benefits expense e) Finance costs Q Depreciation and amortisation expense g) Other expenses 746.67 152.55 638.14 140.69 569.87 1,384.81 293.24 2,344.01 532.62 1,186.97 253.57 126.83 (85.26) 18.52 (66.74) (53.91)84.94 32.66 601.56 11.88 110.81 617.43 12.57 114.51 805.07 537.94 19.61 1,218.99 24.45 225.32 1,524.75 1,081.11 38.12 203.39 1,349.70 2,160.20 75.94 418.12 2,684.85 103.33 719.68 692.00 Total Expenses (IV) 2,363.54 2,241.28 2,134.52 4,145.52 4,604.828,161.83 V Profit before exceptional items & tax (III - IV) 571.43 24.26 572.08 449.84 58.26 1,143.51 24.26 780.35 1,658.95 86.43VI Exceptional items: (Income) / expenses (Refer Note no.4) 58.26 VII Profit before tax (V - VI) 547.17 572.08 391.58 1,119.25 1,572.52722.09 VIII Tax Expense -Current tax -Short / (Excess) provision of earlier years -Deferred tax liability / (asset) / (liability reversal) 147.35 133.21 (0.31) 16.37 108.48 280.56 (0.31) 24.65 203.82 420.63 (2.80) (36.68) 0.44 8.28 (0.40) (0.09) IX Profit for the period before share of profit / (loss) of associates & joint venture (VII-VIII) 391.54 422.81 283.50 814.35 517.92 1,191.37 Add Share of Profit / (less loss) of associates & joint venture (net of tax) X (2.22) 1.46 (2.97) (0.76) (4.50) (7.59) Profit for the period from continuing operations before non - controlling interest Less profit / (add loss) atributable to non-controlling interest XI 389.32 424.27 280.53 813.59 513.42 1,183.78 XII 14.19 22.38 (2.04) 36.57 (2.36) 42.66 XIII Profit for the period attributable to owners of the Company (XI - XII) 375.13 401.89 282.57 777.02 515.78 1,141.12 XIV Other Comprehensive Income (OCI) A. (i) Items that will not be reclassified to profit or loss Actuarial gain / (loss) Tax effect thereon Fair Value change through Other comprehensive income Tax effect thereon B. (i) Items that will be reclassified to profit or loss Exchange difference in translating the financial statement of foreign operation Tax effect thereon C. Share of OCI from investment in associates 4.89 (17.86) 3.31 (12.97) 5.88 14.68 (3.78)(1.06) 4.39 (0.56) 3.33 0.03 1.24 6.35 (6.58) 8.45 (0.23) 10.17 30.92 (0.37) (0.03) (0.12) (0.40) (0.05) (0.50) 0.20 Other Comprehensive Income / (Loss) for the period, net of tax (XIV) 9.81 (20.08) (10.27)11.08 16.03 42.76 XV Total Comprehensive Income for the period (XI + XIV) 399.13 404.19 291.61 803.32 529.45 1,226.54 Profit after tax attributable to Owners of the parent Non-controlling interest - profit / (loss) 375.13 14.19 401.89 22.38 282.57 (2.04) 777.02 36.57 515.78 (2.36) 1,141.12 42.66 389.32 424.27 280.53 813.59 513.42 1,183.78 Other Comprehensive Income for the period attributable to: Owners of the parent Non-controlling interest - profit / (loss) 8.30 (18.63) (1.45) 10.21 (10.33) 13.72 37.10 1.51 0.87 0.06 2.31 5.66 9.81 (20.08) 11.08 (10.27) 16.03 42.76 to : Owners of the parent Non-controlling interest - profit / (loss) 383.43 15.70 383.26 20.93 292.78 (1.17) 766.69 36.63 529.50 (0.05) 1,178.22 48.32 399.13 404.19 291.61 803.32 529.45 1,226.54 XVI Paid-up equity share capital (Face value oft 1/- each) 25.37 25.37 25.37 25.37 25.37 25.37 XVII Other Equity XVIM_ Net Worth /^XIX Earning per equity share (oft 1/-each) (Not annualise^ 8,038.44 8,063.81 2®* ? //'. basic',, ;'^llOted (Before Exceptional items) (t) / ijp 'rPiKil^d (After Exceptional items) (t) / C\15-29 L 12.114.79 15.84 15.84 12.35 31,13 30.63 21.54 20.33 46.94 44.98ir 11.14 < TO v-a ~o cbo- * ★★ir
Page 9
: 2 : Ipca Laboratories Limited Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067 GIN : L24239MH1949PLC007837 Tel:+91 22 6647 4444. E-mail: investors@ipca.com Website : www.ipca.com STATEMENT OF UNAUDITED CONSOLIDATED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026 (? Crores) Sr. No. Particulars As at September 30, 2026 Unaudited As at March 31, 2026 Audited A ASSETS : Non-current assets : Property, Plant & Equipment Capital work-in-progress Goodwill on consolidation Goodwill on acquisition Other Intangible assets Intangible assets under development Right of use assets Biological assets other than Bearer Plant Investment accounted for using the equity method Financial Assets (i) Investments (ii) Loans (iii) Others Deferred tax assets (net) Other non-current assets Total Non-Current Assets Current assets : Inventories Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank Balance other than (iii) above (v) Loans (vi) Others Current tax assets (net) Other current assets Total Current Assets Non-current assets classified as held for sale Total Assets 1 (a) 4,281.58 831.52 82.81 4,180.29 761.59 82.81 (b) (c) (d) (e) 97.80 13.40 263.77 103.27 11.50 260.30 (0 (9) (h) 0.22 0.22 (i) 182.90 183.61 (j) 26.54 26.53 14.47 95.22 20.54 252.98 5.29 95.81 23.24 300.94 (k) (I) 6,205.82 5,993.33 2 (a) 2,937.78 2,731.00 (b) 845.53 2,395.06 207.13 58.25 48.06 37.40 633.42 2,014.26 437.12 127.47 49.83 17.69 (C) (d) 394.68 362.82 6,923.89 6,373.61 3 3.22 3.25 13,132.93 12,370.19 B EQUITY AND LIABILITIES : Equity : Equity Share Capital Other Equity Equity attributable to owners of the Holding Company Non controlling interest Total Equity 1 (a) 25.37 8,652.96 25.37 8,038.44(b) 8,678.33 1,495.38 8,063.81 1,460.25 10,173.71 9,524.06 2 Liabilities : Non-current liabilities : Financial Liabilities (i) Borrowings (ii) Lease liability (iii) Other financial liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Total Non-Current Liabilities Current liabilities : Financial Liabilities (i) Borrowings (ii) Lease liability (iii) Trade payables . - Dues of micro and small enterprises - Dues of others (iv) Other financial liabilities (a) 67.35 106.81 109.12 86.89 (b) 104.44 273.54 97.91 244.86(C) (d) 0,19 0.42 552.33 539.20 ii (a) 558.90 19.70 594.82 17.93 149.65 924.71 387.13 181.68 109.70 75.42 148.69 791.60 449.35 158.30 87.46 58.78 Provisions Other current liabilities ^yrr;ent Tax Liabilities (net) Li^bi[\tr,es associated with non-current assets held for sale jfTotal Current Liabilities y#7^: ■ (d),<o o-Q. e < 2,406.89'r'.V 2,306.93 Total Equity and Liabilities 13,132.93 12,370.19 V ¥ * y /*
Page 10
: 3 : Ipca Laboratories Limited Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067 CIN : L24239MH1949PLC007837 Tel:+91 22 6647 4444, E-mail: investors@ipca.com Website : www.ipca.com STATEMENT OF UNAUDITED CONSOLIDATED CASH FLOW FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026 (? Crores) Half Year Ended Particulars September 30, 2026 Unaudited September 30, 2025 Unaudited A. Cash Flow from Operating Activities 1) Net profit before taxation and after exceptional items Adjustments for: Depreciation, amortization and impairment expense (Profit) / Loss on sale of Property, plant & equipment Impairmement loss on property, plant and equipment Net (gain)/ loss on financial asset through FVTPL Property, plant & equipment scrapped / transferred Sundry balances written off / (back) Provision for doubtful debts / advances Provision for Claims Provision for Europeon Commission Fine Bad debts written off Unrealised foreign exchange (gain) / loss Fair value changes- Biological assets (gain) / loss Impairment of Intangibles assets Imapirement of financial assets Deferred ESOP Compensation Claims receivable written off Interest income Interest expense 2) Operating profit before working capital changes Decrease / (Increase) in Inventories Decrease / (Increase) in Trade Receivables Decrease / (Increase) in Other Financial assets Decrease / (Increase) in Other assets Increase / (Decrease) in Trade Payables Increase / (Decrease) in Other Financial liabilities Increase / (Decrease) in Other liabilities Increase / (Decrease) in Provisions 3) Cash generated from operation Income tax paid (net) Net cash from operating activities B. Cash Flow from Investing Activities Purchase of Property, plant & equipment including capital Work in progress and Intangible assets Capital Incentive Proceeds from Sale of Property, Plant and Equipment Proceeds from disposal of non current assets held for sale Loan given - Associate & Joint Venture Loan recovered- Associate & Joint Venture Loan given - Others Loan recovered - Others Movement in other bank balances Interest received Net cash from / (used in) investing activities C. Cash Flow from Financing Activities Increase / (decrease) in short term borrowings Repayment of long-term borrowings Payment of principal portion of Lease liability Payment of Interest portion of Lease liability Interest paid Dividend & dividend tax paid Net cash from / (used in) financing activities Net increase / (decrease) in cash and cash equivalents ( A + B + C ) Cash and cash equivalents at beginning of year Cash and cash equivalents at end of the year Components of cash & cash equivalents : Cash and cheques on hand Balance with banks Mutual Funds Less : Fair value (gain) / loss on Mutual funds 1,119.25 722.09 225.32 (3.88) 203.39 0.56 3.12 (2.12) (2.30) 0.11 0.96 (0.12) (0.17) 2,58 0.18 24.26 58.26 0.82 0.02 10.43 42.58 0.05 6.01 7.77 9.58 14.78 0.16 0.50 1.20 (19.46) 24.45 (14.69) 38.12278.14 354.33 1,397.39 1,076.42 (206.78) (364.57) (6.81) (59.90) 132.75 (71.99) 22.01 (7.35) 44.55 (152.27) (7.99) (19.37) (25.04) 25.36 9.67 (562.64) 24.40 (100.69) 834.75 (261.43) 975.73 (195.67) 573.32 780.06 (442.81) (461.47) 20.96 4.64 1.41 36.90 (7.55)(2.35) 3.05 5.81 (9.00) (8.95) 9.25 0.25 74.27 119.30 0.79 16.09 (341.20) (298.21) 10.48 14.83 (124.66) (6.30) (1.88) (39.85) (52.72) (87.84) 4.05 (3.84) (21.08) (153.89) (252.12) (210.58) (20.00) 1,066.30 271.27 924.63 1.046.30 1,195.90 5.56 2.68 201.57 210.27 845.53 (6,36) 991.18 (8,23)839,17 982.95 1.046.30 1,195.90 By Order of the Board For Ipca Laboratories Limitei 0,\.ooe^ <y.■o 3to A.K. Jain , ^ ,\ cO Managing Director o (DIN 00012657)\9:'X-------- - , ■ ^ s' Place : Mumbai Date : November 05, 2026 pjpV? r" V • tnv \( *
Page 11
: 4 : Notes: These consolidated financial results relate to Ipca Laboratories Limited (the 'Company'), its Subsidiaries (together the 'Group'), Joint Venture am prepared by applying Ind AS 110 - "Consolidated Financial Statements" and Ind AS 28 - "Investments in Associates and Joint Ventures. The above consolidated financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on November 05, 2026. The Statutory auditors of the Company have carried out Limited Review of the unaudited consolidated financial results and have issued unmodified report thereon. The above financial results are prepared in accordance with the Indian Accounting Standards (IND-AS) as prescribed under Section 133 of the Companies Act, 2013 and are in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 (as Amended). 1 2 3 Exceptional items :4 ( ? crores ) Sr. No. Particulars Quarter Ended Half Year Ended Year Ended Sept 30, 2026 June 30, 2026 Sept 30, 2025 Sept 30, 2026 Sept 30, 2025 Mar 31,2026 Interest settlement of Europeon Commission Impact of new Labour Codes Net (gain)/ loss on disposal of land & building Provision for Claims a. 58.26 58.26 58.26 45.82 (17.65) b. c. d. 24.26 24.26 Total 24.26 58.26 24.26 58.26 86.43 Disclosure on above: Interest settlement of Europeon Commission During the previous year, In continuation of the pending litigation, Unichem Laboratories Limited and its subsidiary Niche Generics Ltd. ("Niche") has received a demand order dated September 17, 2025 from the European Commission (EU) for payment of fine and interest aggregating to Euro 19.55 million (INR 203.89 Crores) and the same is fully settled by Unichem on October 28, 2025 after adjusting the payments of Euro 2.79 million (INR 29.12 Crores) already made by Niche in instalments to EU. In regard to above, Unichem had fully recognised a provision in its books towards payment of fine amounting to Euro 13.96 million (INR 125 62 Crores) towards EU fine during year ended March 31, 2024 and the balance amount of INR 58.26 Crores representing the interest is recorded during the’ previous year under exceptional items by the said Unichem. Impact of new Labour Codes During the previous year, On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes’) which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to gratuity and leave. The Holding Company and its subsidiary companies assessed the financial implications of these changes which has resulted in increase in gratuity and leave liability arising out of past service cost by ? 45.82 crores for the year ended March 31, 2026. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this amount as "Impact of new Labour Codes" under “Exceptional Item" in the Statement of Profit and Loss for the year ended March 31, 2026. Net (gain)/ loss on disposal of land & building During the previous year, the Unichem Laboratories Limited has entered into a deed of conveyance dated 9th October 2025 with Lodha Developers Limited (formerly known as ''Macrotech Developers Limited") for sale of freehold land and building situated at Prabhat Estate, off S.V, Road, Jogeshwari (West), Mumbai 400J62 at an agreed consideration of ? 279 crores resulting in a gain (net of related expenses) of ? 17.65 crores in consolidated result, which has been recorded as an exceptional item. a. b. c. d. Provision for Claims Laboratories Servier had filed a claim against Niche Generics Limited ("Niche"), and its parent company, Unichem Laboratories Limited ("Unichem"), amongst others, seeking a contribution towards damages claimed by UK Health Authorities in relation to Perindopril proceedings in the UK. In view of the significant legal costs involved, Niche Generics Limited intends to resolve the matter at the earliest opportunity and by compromise if possible. Accordingly, a provision of £1.9 million (equivalent to ? 24.26 crores) has been recognised as an exceptional item in the books of Niche and consolidated financial results of Unichem for the quarter and half year ended 30 September 2026. During the previous year, other income includes an amount of ? 60.04 crores Gain on deconsolidation pursuant to sale of Baysnore Pharmaceuticals LLC a subsidiary of the group. 5 At the meeting of the Board of Directors of the Company held on June 26, 2026, it was resolved to amalgamate M/s. Krebs Biochemicals & Industries Ltd. with the Company, subject to necessary consents/approvals. The appointed date for this amalgamation is April 1, 2026. However, pending consents/approvals, no e'fect for this amalgamation has been given in the unaudited financial results. In accordance with Ind AS-108 "Operating Segments", the operations of the Group are categorised in one segment viz Pharmaceuticals. The geographic information of the Group's revenues by the Company's country of domicile and other countries is tabulated hereunder: 6 7 (? crores ) Particulars Quarter Ended Half Year Ended Year Ended Sept 30, 2026 June 30,2026 Sept 30, 2025 Sept 30, 2026 Sept 30, 2025 Mar 31, 2026 Segment Revenue - India - Outside India 1,356.77 1,553.17 1,229.21 1,558.89 1,162.52 1,393,98 2,585.98 3,112.06 2,245.69 2,619,66 4,386.62 5,259.71 Total 2,909,94 2,788.10 2,556.50 5,698.04 4,865.35 9,646.33 The geographic information of the Non-current assets "outside India" is less than 10% of the total Non-current assets of the Group and therefore, not disclosed separately. Figures for the previous period have been regrouped to conform to the figures of the current period's classification wherever necessary.8 By Order of the Board For Ipca Laboratories Limited is: A.K. Jain Managing Director (DIN 00012657) Place : Mumbai Date : November 05, 2026
Page 12
N V C & Associates LLP Chartered Accountants 903-904,9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email: nvc@nvc.in LLPIN - ACM-9656 Independent Auditor's Review Report on Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2026, of IPCA Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as Amended) To, The Board of Directors of Ipca Laboratories Limited, 1. We have reviewed the accompanying statement of unaudited consolidated financial results of Ipca Laboratories Limited (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income of its joint ventures and associates for the quarter and half year ended September 30, 2026 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). 2. Management's responsibility This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion in our report on this Statement of unaudited consolidated financial results based on our review. 3. Auditor's Responsibility Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. urfflia/★ *<5 5$
Page 13
N V C S* Associates LI<F Chartered Accountants 903-904,9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email: nvc@nvc.in LIPIN -ACM-9656 We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes unaudited standalone financial results of the following entities:5. Name of the EntitiesSr. No. Ipca Laboratories Limited - Holding Company Subsidiaries Ipca Pharma Nigeria Limited, Nigeria1 Ipca Laboratories (U.K.) Limited, UK2 Ipca Pharmaceuticals,Inc (USA)3 Ipca Pharma (Australia) Pty Limited, Australia4 Trophic Wellness Private Limited5 Unichem Laboratories Limited6 Ipca Pharmaceuticals Limited , Ireland (Formerly, Unichem Laboratories Limited, Ireland) 7 Ipca Pharmaceuticals Gmbh8 Step down Subsidiaries Onyx Scientific Limited, UK1 Ipca Pharma (NZ) Pty Limited, New Zealand2 Pisgah Labs Inc., USA3 Niche Generics Limited, United Kingdom5 Unichem Pharmaceuticals (USA), Inc., USA6 Unichem SA (Pty) Limited, South Africa7 Unichem Farmaceutica Do Brasil Ltda, Brazil8 Unichem (China) Pvt. Ltd.9 Associate Krebs Biochemicals & Industries Limited1 Joint Venture Avik Pharmaceuticals Limited1 Lyka Labs Limited2
Page 14
N V C & Associates LLP Chartered Accountants 903-904,9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email: nvc@nvc.in LLPIN - ACM-9656 6. Based on our review conducted and procedures performed as stated in paragraph 3 and 4 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 7. Other Matter a) We did not review the special purpose consolidated financial results of one subsidiary, whose consolidated financial results reflect total assets of Rs. 3905.28 Crores, total revenue of Rs. 1303.82 Crores and net profit after tax of Rs. 61.13 Crores and total comprehensive income of Rs 61.27 Crores for the half year ended September 30, 2026, before giving effect to elimination of intra-group transactions as considered in the preparation of the consolidated financial results. These special purpose financial statements have been prepared for the purposes of harmonizing accounting policy as followed by parent company for inventory valuation i.e. change the cost formula followed by the subsidiary company from weighted average to First in First out and have been reviewed by other auditors whose report has been furnished to us by the Management and Our conclusion on the statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter. b) These consolidated financial results also include the Group's share of loss after tax of Rs 2.54 crores and Total Comprehensive loss of Rs 2.54 crores in respect of one associate and one joint venture, for the half year ended September 30, 2026, as considered in the Statement. These unaudited financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associates and joint venture, are based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters. c) We also did not review the financial results of ten subsidiaries whose financial results reflects, total assets Rs. 1,263.94 crores total revenues Rs. 259.23 Crores, net profit after tax of Rs 4.56 Crores and Total Comprehensive loss of Rs 9.11 crores for the half year ended September 30, 2026, as considered in these financial results. The consolidated financial results also include the Group's share of net profit of Rs 1.78 crores and Total Comprehensive income of Rs 1.78 crores in respect of 1 joint ventures. These financial statements of immaterial subsidiaries and joint venture have been prepared by the management for consolidation purposes and are bai +
Page 15
N V C & Associates LLP Chartered Accountants 903-904,9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email: nvc@nvc.in LIPIN -ACM-9656 incorporated in these consolidated financial statements on the basis of the management accounts on which we have not carried out any review procedures. Our conclusion is not modified on this account. For N V C & Associates LLP Chartered Accountants Firm Registration No. 106971W/W101085 ? Mumbai -N Jayendran \ Partner Membership. No. 040441 Mumbai Dated: November 05, 2026 UDIN: 26040441QPTYG12532 C r-o 9 £
Page 16
A dose of life PRESS RELEASE Ipca Laboratories Q2/H1 FY27 Financial Results Mumbai, November 5, 2026 : Ipca Laboratories Limited today announced its unaudited financial results for the second quarter and half year ended 30th September, 2026. Key Financials of 02 FY27 Standalone Net total Income up 17% at Rs. 2274.53 crores. Consolidated Net total Income up 14% at Rs. 2934.97 crores. Indian formulations income up 14% at Rs 1157.20 crores. Exports Income up 17% at Rs. 951.39 crores. Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 26.61 % in Q2 FY27 as against @ 25.46% in Q2 FY26. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.97% in Q2 FY27 as against @ 21.68% in Q2 FY26. Standalone Net Profit at Rs. 387.29 crores (after exceptional items) up 27%. Consolidated Net Profit at Rs. 375.13 crores (after exceptional items) up 33%. Standalone Q2 FY27 at a glance (Rs. Crores) Particulars Q2FY27 Q2 FY26 Growth Revenue from Operations 2255.61 1930.32 17% Export Income 951.39 813.65 17% EBITDA before Forex (gain) / loss, other income and exceptional items 600.22 491.47 22% Other Income 18.92 21.92 -14% Forex (gain) / loss 3.16 26.76 Finance Cost 4.68 11.46 -59% Depreciation and Amortisation 77.59 66.86 16% Exceptional items: (income) / expenses Tax Expense 146.42 103.57 41% Net Profit after tax 387.29 304.74 27% Earnings per share of Re. 1/- each (Rs.)(Before exceptional items) 15.27 12.01 27% Earnings per share of Re. 1/- each (Rs.)(After exceptional items) 15.27 12.01 27% Ipca Laboratories Ltd. www.ipca.com 125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | I:+91 22 6210 5000 F:+91 22 6210 5005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444 E: ipca@ipca.com CIN: L24239MH1949PLC007837
Page 17
^£ipca ■ A dose of life :2: Consolidated Q2 FY27 at a glance (Rs. Crores) GrowthQ2FY26Q2FY27Particulars 14%2556.502909.94Revenue from Operations 21%EBITDA before Forex (gain) / loss, other income and exceptional items 554.31668.27 -10%27.8625.03Other income (5.21) 9.39Forex (gain) / loss -36%19.6112.57Finance Cost 103.33 11%Depreciation and Amortisation 114.51 58.26Exceptional items: (income) / expenses 24.26 44%108.08155.63Tax Expense Profit for the period including share of non - controlling interest but before share of profit / (loss) of associates & joint venture 38%391.54 283.50 (2.97)Add share of profit / (less loss) of associates & joint venture (2.22) Less profit / (add loss) attributable to non - controlling interest. (2.04)14.19 Net Profit after tax 33%282.57375.13 Earnings per share of Re. 1/- each (Rs.) (Before exceptional items) 24%15.29 12.35 Earnings per share of Re. 1/- each (Rs.) (After exceptional items)___________________________ 33%11.1414.79 I pea Laboratories Ltd. www.ipca.com T:+91 22 6210 5000 F:+91 22 6210 5005 T: +91 22 6647 4444 125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India E: ipca@ipca.com CIN: L24239MH1949PLC007837
Page 18
:3: A dose of life Q2 FY27 Revenue break-up (Rs. Crores) Particulars Q2 FY27 Q2 FY26 Growth Formulations Domestic Exports Branded Institutional Generics 1157.20 1018.90 14% 172.50 115.76 364.48 145.04 79.66 268.01 19% 45% 36% Total Formulations 1809.94 1511.61 20% APIs Domestic Exports 135.56 298.65 86.84 320.94 56% -7% Total APIs 434.21 407.78 6% Other Operating Income 11.46 10.93 5% Standalone Revenue from Operations 2255.61 1930.32 17% Revenue from Operations - Subsidiaries 654.33 626.18 4% Consolidated Revenue from Operations 2909.94 2556.50 14% Other Income 25.03 27.86 -10% Consolidated Net Total Income 2934.97 2584.36 14% Key Financials of HI FY27 Standalone Net Total Income up 18% at Rs. 4411.19 crores. Consolidated Net Total Income up 17% at Rs. 5748.33 crores. Indian formulations income up 13% at Rs. 2239.32 crores. Exports Income up 25% at Rs. 1886.78 crores. Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 26.45% in FY27 as against @ 24.68% in FY26. Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 22.92% in FY27 as against @ 20.12% in FY26. Standalone Net Profit at Rs. 760.58 crores (after exceptional items) up 34%. Consolidated Net Profit at Rs. 777.02 crores (after exceptional items) up 51%. Ipca Laboratories Ltd. www.ipca.com 125, Kandivli Industrial Estate, CIS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444 E: ipca@ipca.com CIN: L24239MH1949PLC007837
Page 19
A: A dose of life Standalone HI FY27 at a glance (Rs. Crores) Particulars HI FY27 HI FY26 Growth Revenue from Operations 4374.85 3677.22 19% Export Income 1886.78 1513.41 25% EBITDA before Forex (gain) / loss, other income and exceptional items 1157.04 907.51 27% Other income 36.34 46.94 -23% Forex (gain) / loss (17.66) 35.88 Finance Cost 9.72 23.52 -59% Depreciation and Amortisation 152.20 129.99 17% Exceptional items : (income) / expenses Tax Expense 288.54 198.28 46% Net Profit after tax 760.58 566.78 34% Earnings per share of Re. 1 /- each (Rs.) (Before exceptional items) 29.98 22.34 34% Earnings per share of Re. 1/- each (Rs.) (After exceptional items) 29.98 22.34 34% Consolidated HI FY27 at a glance (Rs. Crores) Particulars HI FY27 HI FY26 Growth Revenue from Operations 5698.04 4865.35 17% EBITDA before Forex (gain) / loss, other income and exceptional items 1306.21 978.89 33% Other Income 50.29 60.52 -17% Forex (gain) / loss (36.78) 17.55 Finance Cost 24.45 38.12 -36% Depreciation and Amortisation 225.32 203.39 11% Exceptional items: (income) / expenses 24.26 58.26 Tax Expense 304.90 204.17 49% Profit for the period including share of non - controlling interest but before share of profit / (loss) of associates & joint venture 814.35 517.92 57% Add share of profit / (less loss) of associates & joint venture (0.76) (4.50) Less profit / (add loss) attributable to non - controlling interest. 36.57 (2.36) Net Profit after tax 777.02 515.78 51% Earnings per share of Re. 1/- each (Rs.) (Before exceptional items) 31.13 21.54 45% Earnings per share of Re. 1/- each (Rs.) (After exceptional items) 30.63 20.33 51% V Ln ’•v I pea Laboratories Ltd. www.ipca.com /Industrial Estate, CIS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444 E: ipca@ipca.com CIN: L24239MH1949PLC007837 S c Cl a 3 sj 25, Kar\Q T+3
Page 20
:5: A dose of life HI FY27 Revenue break-up (Rs. Crores) Particulars FY27 FY26 Growth Formulations Domestic 2239.32 13%1979.91 Exports Branded Institutional Generics 315.77 235.51 18%268.63 137.49 71% 31%704.50 536.20 Total Formulations 3495.10 2922.23 20% APIs Domestic Exports 226.93 631.00 39%163.03 10%571.09 Total APIs 857.93 734.12 17% Other Operating Income 21.82 5% 20.87 Standalone Revenue from Operations 4374.85 19%3677.22 Revenue from Operations - Subsidiaries 1323.19 1188.13 11% Consolidated Revenue from Operations 17%5698.04 4865.35 Other Income 50.29 -17%60.52 Consolidated Net Total Income 5748.33 4925.87 17% About Ipca Laboratories: Ipca is a fully integrated pharmaceutical company with a strong thrust on exports, ipca is vertically integrated and produces Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs). A.K. Jain Managing DirectorX^ * Enel: Unaudited Standalone & Consolidated Financial Results Contact Information: Harish P. Kamath, Corporate Counsel & Company Secretary at harish.kamathrajpca.com or on +91 -22- 6210 6050 Ipca Laboratories Ltd. www.ipca.com 125, Kandivli Industrial Estate, CIS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T:+91 22 6210 5000 F:+91 22 6210 5005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444 E: ipca@ipca.com ON: L24239MH1949PLC007837